Antifungals inhibitors of glucan synthesis;Antifúngicos inhibidores de la síntesis del glucano

Revista Espanola de Quimioterapia

Volumn 18, Issue 4, 2005, Pages 281-299

  Romero, M ^a   Canton E ^a   Peman J ^a   Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACULEACIN A; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CILOFUNGIN; CYCLO[THREONYL(4 HYDROXYPROLYL)(3,4 DIHYDROXYHOMOTYROSYL)(3 HYDROXYGLUTAMINYL)(3 HYDROXY 4 METHYLPROLYL) NGAMMA (4,5 DIHYDROXYORNITHINE)] NALPHA (10,12 DIMETHYLTETRADECANOYLAMIDE); CYCLOSPORIN; ECHINOCANDIN B; ECHINOCANDIN C; ECHINOCANDIN D; FLUCYTOSINE; FR 135131; FR 901370; GLUCAN; ITRACONAZOLE; L 688786; L 693989; L 731373; L 733560; L 767812; L 773560; LY 693989; MICAFUNGIN; MYCOPHENOLIC ACID; PAPULACANDIN B; PNEUMOCANDIN DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WF 11899; WF 1899;

AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDIASIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HEMOLYSIS; HUMAN; LIVER TOXICITY; MYCOSIS; REVIEW;

AMINOGLYCOSIDES; ANTIFUNGAL AGENTS; GLUCANS; GLUCOSYLTRANSFERASES; HUMANS; PEPTIDES, CYCLIC; TRITERPENES;

EID: 33644540481     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Vaqué, J., Roselló, J. (Eds.). Proyecto Epine. Evolución de la prevalencia de las infecciones nosocomiales en los hospitales españoles. Epine 1990-1999. Sociedad Española de Medicina Preventiva, Salud Publica e Higiene, Madrid 2001.
2. Groll, A.H., Shah, P.M., Mentzel, C. y cols. Trends in the post mortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 23: 23-32.
3. Kartsonis, N.A., Nielsen, J., Douglas, C.M. Caspofungin: The first in a new class of antifungal agents. Drug Resistance Updates 2003; 6: 197-218.
4. Onishi, J., Meinz, M., Thompson, J. y cols. Discovery of novel antifungal (1,3)-β-D-glucan sinthase inhibitors. Antimicrob Agents Chemother 2000; 44: 368-377.
5. Traxier, P., Gruner, J., Auden, J.A.L. Papulacandins, a new family of antibiotics with antifungal activity. Isolation, chemical and biological characterization of papulacandins A, B, C, D and E. J Antibiot 1977; 30: 289-296.
6. De Lucca, A.J., Walsh, T.J. Antifungal peptides: Novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 1999; 43: 1-11.
7. Traxier, P., Fritz, H., Fuhrer, H. y cols. Papulacandins, a new family of antibiotics with antifungal activity. J Antibiot 1980; 33: 967-978.
8. Hector, R.F. Compounds active against cell walls of medically important fungi. Clin Microbial Rev 1993; 6: 1-21.
9. Yeung, C.M., Klein, L.L., Lartey, P.A. Preparation and antifungal activity of fusacandin analogs: C-6′sidechain esters. Bioorg Med Chem Lett 1996; 6: 819-822.
10. Carrillo-Muñoz, A.J., Pemán, J., Gobernado, M. Nuevos antifúngicos. Presente y futuro. Rev Esp Quimioterap 1999; 12: 181-204.
11. Cabello, M.A., Platas, G., Collado, J. y cols. Arundifungin, a novel antifungal compound produced by fungi: Biological activity and taxonomy of the producing organisms. Int Microbiol 2001; 4: 93-102.
12. Gorman, J.A., Chang, L. P., Clark, J. y cols. Ascosteroside, a new antifungal agent from Ascotricha amphitricha. 1. Taxonomy, fermentation and biological activities. J Antibiot (Tokyo) 1996; 49: 547-552.
13. Leet, J.E., Huang, S., Kiohr, S.E. y cols. Ascosteroside, a new antifungal agent from Ascotricha amphitricha. 2. Isolation and structure elucidation. J Antibiot (Tokyo) 1996; 49: 553-559.
14. Kumeda, Y., Asao, T., Iida, A. y cols. Effects of ergokonin A produced by Trichoderma viridae on the growth and morphological development of fungi. J Antibacteriol Antifungal Agents Jpn 1994; 22: 663-670.
15. Liesch, J.M., Meinz, M., Onishi, G.J. y cols. 27 January 1998; U.S. Patent 5,712,109.
16. Cassone, A., Mason, R.E., Kerridge, D. Lysis of growing yeast-form cells of Candida albicans by echinocandin: A cytological study. Sabouraudia 1981, 19: 97-110.
17. Kurtz, M.B., Douglas, C., Marrinan, J. y cols. Increased antifungal activity of L-733,560, a water-soluble, semisinthetic pneumocandin, is due to to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother 1994; 38: 2750-2757.
18. Ernst, E.J., Klepser, M.E., Ernst, M.E., Messer, S.A., Pfaller, M.A. In vitropharmacodynamic properties of MK-0991 (L-743,872) determined by time-kill methods. Diagn Microbiol Infect Dis 1999; 33: 75-80.
19. Bartizal, K., Gill, C.J., Abruzzo, K. y cols. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-2332.
20. Espinel-Ingroff, A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY 303366 against opportunistic filamentous and dimorphic fungi and yeast. J Clin Microbiol 1998; 36: 2950-2956.
21. Kurtz, M.B., Heath, I.B., Marrinan, J., Dreikorn, S., Onishi, J., Douglas, C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-1489.
22. Bowman, J.C., Hicks, P.S., Kurtz, M.B. y cols. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-3012.
23. Munro, C.A., Gow, N.A. Chitin synthesis in human pathogenic fungi. Med Micol 2001; 39 (Suppl. 1): 41-43.
24. Douglas, C.M., Marrinan, J.A., Li, W., Kurtz, M.B. A Saccharomyces cerevisiae mutant with echinocandin resistant 1,3-β-D-glucan synthase activity. J Bacteriol 1994; 176: 5686-5696.
25. Kondoh, O., Takasuka, T., Arisawa, M., Aoki, Y., Watanabe, T. Differential sensitivity between Fks1p and Fks2p against a novel β-1,3-glucan synthase inhibitor, aerothricin 1. J Biol Chem 2002; 277: 41744-41749.
26. Liu, J., Balasubramanian, M.K. 1,3-β-glucan synthase: A useful target for antifungal drugs. Curr Drug Targets Infect Disord 2003; 1: 159-169.
27. Thompson, J.R., Douglas, C.M., Li, W. y cols. A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. J Bacteriol 1999; 181: 444-453.
28. Douglas, C.M. Fungal beta-(1,3)-D-glucan synthesis. Med Micol 2001; 29 (Suppl. 1): 55-56.
29. Campbell, J.A., Davies, G.J., Bulone, V., Henrissat, B. A classification of nucleotide-diphospho-sugar glycosyltransferases based on ammo acid sequence similarities. Biochem J 1997; 326 (Prt. 3): 929-939.
30. Radding, J.A., Heidler, S.A., Turner, W.W. Photoaffinity analog of the semisynthetic echinocandin LY303366. Identification of echinocandin targets in Candida albicans. Antimicrob Agents Chemother 1998; 42: 1187-1194.
31. Denning, D.W. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151.
32. Kurtz, M.B., Rex, J.H. Glucan synthase inhibitors as antifungal agents. Adv Protein Chem 2001; 56: 423-475.
33. Popolo, L., Gualtieri, T., Ragni, E. The yeast cell-wall salvage pathway. Med Micol 2001; 39 (Suppl. 1): 111-121.
34. Osherov, N., May, G.S., Albert, N.D., Kontoyiannis, D.P. Overexpression of Sbe 2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002; 46: 2462-2469.
35. Franzot, S.P., Casadevall, A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997; 41: 331-336.
36. Del Poeta, M., Cruz, M.C., Cárdenas, M.E., Perfect, J.R., Heitman, J. Synergistic antifungal activities of bafilomycin A(1), fluconazole and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK-506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother 2000; 44: 739-746.
37. Turner, W.W., Current, W.L. Echinocandin antifungal agents. En: Strohl, W.R. (Ed.). Biotechnology of antibiotic, 2nd ed. Marcel Dekker, Inc., New York 1997; 315-334.
38. Georgopapadakou, N.H., Walsh, T.J. Antifungal agents: Chemotherapeutics targets and immunologic strategies. Antimicrob Agents Chemother 1996; 40: 279-291.
39. Kurtz, M.B., Douglas, C.M. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Micol 1997; 35: 79-86.
40. Keller-Jusien, C., Huhn, M., Loosli, H.R., Petcher, T.P., Weber, H.P., Von Varthurg, A. Strucktur des cyclopeptid amtibiotikums SL-7810 (= echinocandin B). Tetrahedron Lett 1976; 46: 4147-4150.
41. Nyfeler, R., Keller, S.W. Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide antibiotic from Aspergillus nidulans var. echinulatus: Isolation and structural components. Helv Chim Acta 1997; 57: 2459-2477.
42. Beaulieu, A., Tang, D.J., Zeckner, D.J., Parr, T.R. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-β-D glucan synthase. Ferns Microbiol Lett 1993; 108: 133-138.
43. Mizoguchi, J., Saito, T., Mizuno, K., Hayano, K. On the mode of action of new antifungal antibiotic, aculeacin A: Inhibition of cell wall synthesis in Saccharomyces cerevisiae. J Antibiot 1997; 30: 308-313.
44. Pérez, P., Varona, R., García-Acha, I., Durán, A. Effect of papulacandin B and aculeacin A on β-(1,3) glucan synthase from Geotrichum latis. FEBS Lett 1981; 129: 249-252.
45. Sawistowska-Schroder, E.T., Kerridge, D., Perry, H. Echinocandin inhibition of (1,3)-β-D glucan synthase from Candida albicans. FEBS Lett 1984; 173: 134-138.
46. Baguley, B.C., Rommele, G., Gruner, J., Wehrlli, W. Papulacandin B: An inhibitor of glucan synthesis in yeast spheroplasts. Eur J Biochem 1979; 97: 345-351.
47. Bartizal, K., Abruzzo, G., Trainor, C. y cols. In vitro antifungal activities and in vivo efficacies of (1,3)-β-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B and L-687,781, a papulacandin. Antimicrob Agents Chemother 1992; 36: 1648-1657.
48. Gruner, J., Traxler, P. Papulacandin, a new antibiotic, active especially against yeast. Experientia 1997; 33: 137.
49. Balkovec, J.M., Black, R.M., Hammond, M.L. y cols. Synthesis, stability and biological evaluation of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia. J Med Chem 1992; 35: 194-198.
50. Schmatz, D.M., Romancheck, M.A., Pittarelli, L.A., Schwartz, R.E., Fromtting, R. Treatment of Pneumocystis carinii pneumonia with (1,3)-β-D-glucan synthesis inhibitors. Proc Natl Acad Sci USA 1990; 87: 5950-5954.
51. Benz, F., Knuesel, F., Knesch, J. y cols. Echinocandin B, ein neuartiges polypetid antibioticum aus Aspergillus nidulans var echinlatus: Isolierungund baudsteine. Helv Chim Acta 1985; 57: 2459-2477.
52. Traher, R., Keller-Jusien, C., Loosli, H.R., Huhn, M., Von Varthurg, A. Cyclopeptide-amtibiotika aus Aspergillus arten Structur der echinocandine C und D. Helv Chim Acta 1979; 62: 1252-1267.
53. Debono, M.B., Abbott, J., Fukuda, D. y cols. Synthesis of new analogs of echinocandin B by enzymatic deacylation and chemical reacylation of the echinocandin B peptid: Synthesis of the antifungal agent cilofungin (LY 121019). J Antibiotic 1989; 42: 389-397.
54. Debono, M.B., Abbott, J., Turner, J.R. y cols. Synthesis and evaluation of LY12019, a member of a series of semisynthetic analogue of the antifungal lipopeptide echinocandin B. Annu Rev NY Acad Sci 1988; 544: 152-167.
55. Fromtling, R., Abruzzo, G.K. L-671,329, a new antifungal agent. In vitro activity, toxicology and efficacy in comparison to aculeacin. J Antibiot 1989; 42: 174-178.
56. Gordee, R.S., Zeckner, D.J., Howard, L.C., Alborn, W.E., Jr., Debono, M. Anti-Candida activity and toxicology of LY121019, a novel polypeptide antifungal antibiotic. Ann NY Acad Sci 1998; 544: 295-301.
57. Taft, T.S., Stark, T., Selitrennicoff, C.F. Cilofungin (LY121019) inhibits Candida albicans (1,3)-β-D-glucan synthase activity. Antimicrob Agents Chemother 1988; 32: 1901-1903.
58. Denning, D.W., Stephans, D.A. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 1991; 35: 1329-1333.
59. Pfaller, M., Gordee, R., Gerarden, T., Yu, M., Wenzel, R. Fungicidal activity of cilofungin (LY121019) alone and in combination with anticapsin or other antifungal agents. Eur J Clin Microb Infect Dis 1989; 8: 564-567.
60. Rouse, M.S., Tallan, B.M., Steckelberg, J.M., Henry, N.K., Wilson, W.R. Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 1992; 36: 56-58.
61. Spitzer, E.D., Travis, S.J., Kobayashi, G.S. Comparative in vitro activity of LY121019 and amphotericin B against isolate of Candida species. Eur J Clin Microbiol Infect Dis 1988; 7: 80-81.
62. Walsh, T.J., Lee, J.W., Kelly, P. y cols. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a (1,3)-β-D-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother 1991; 35: 1321-1328.
63. Zambias, R.A., Hammond, M., Heck, J.V. y cols. Preparation and structure-activity relationships of simplified analogues of the antifungal agent cilofungin: Total synthesis approach. J Med Chem 1992; 35: 2843-2855.
64. Denning, D.W. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action. J Antimicrob Chemother 1997; 40: 611-614.
65. Debono, M., Gordee, R.S. Antibiotic that inhibit fungal cell wall development. Annu Rev Microbiol 1994; 48: 471-497.
66. Pfaller, M.A., Messer, S.A., Coffman, S. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivate LY 303366, and other antifungal agents. Antimicrob Agents Chemother 1997; 41: 763-766.
67. Uzun, O., Kocagoz, S., Cetinkaya, Y., Arikan, S., Unal, S. In vitro activity of a new echinocandin, LY203366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 1997; 41: 1156-1157.
68. Pfaller, M.A., Marco, F., Mecer, S.A., Jones, R.N. In vitro activity of two echinocandins derivates, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn Microbiol Infect Dis 1998; 30: 251-255.
69. Oakley, K.L., Moore, C.B., Denning, D.W. In vitro activity of the echinocandin antifungal agent LY303366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1994; 42: 2726-2730.
70. Fromtling, R.A. Micafungin sodium (FK-463). Drugs Today 2002; 38: 245-257.
71. Mikamo, H., Sato, Y., Tamaya, T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 2000; 46: 485-487.
72. Ikeda, F., Wakai, Y., Matsumoto, S. y cols. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000; 44: 614-618.
73. Ito, M., Nozu, R., Kuramochi, T. y cols. Prophylactic effect of FK 463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000; 44: 2259-2262.
74. Schwarts, R.E., Sesin, D.F., Joshua, H. y cols. Pneumocandins from Zalerion arboricola. I. Discovery and isolation. J. Antibiot 1992; 45: 1853-1865.
75. Gordee, R.S., Zeckner, D.J., Ellis, L.F., Thakker, A.L., Howard, L.C. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J Antibiot 1984; 37: 1054-1065.
76. Schmatz, D.M., Abruzzo, G., Powles, M.A. y cols. Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. J Antibiot 1992; 45: 1886-1891.
77. Denning, D.W. Echinocandins: A new class of antifungal. J Antimicrob Chemother 2002; 49: 889-891.
78. Bartizal, K., Scott, T., Abruzzo, G.K. y cols. In vitro evaluation of the pneumocandin antifungal agent L733560, a new water-soluble hybrid L705589 and L731373. Antimicrob Agents Chemother 1995; 39: 1070-1076.
79. Martínez-Suárez, J.V., Rodríguez-Tudela, J.L. In vitro activities of semisynthetic pneumocandin L-733560 against fluconazole-resistant and susceptible Candida albicans isolates. Antimicrob Agents Chemother 1996; 40: 1277-1279.
80. Zambias, R.A., James, C., Abruzzo, G.K. y cols. Lipopeptide antifungal agents: Amine conjugates of the semi-synthetic pneumocandins L-731,373 and L-733,560. Bioorg Med Chem Lett 1997; 7: 2021-2026.
81. Del Poeta, M., Schell, W.A., Perfect, J.R. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinical important molds. Antimicrob Agents Chemother 1997; 41: 1835-1836.
82. Merck & Co. Press release, business wire. Data on file. Merk & Co., White House Station N.J., May 21, 1996.
83. Krishnarao, T.V., Galgiani, J.N. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991 and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997; 41: 1957-1960.
84. Mizuno, K., Yagi, A., Satoi, S. y cols. Studies on aculeacin. I. Isolation and characterization of aculeacin A. J Antibiot 1977; 30: 297-302.
85. Satoi, S., Yagi, A., Asano, K., Mizuno, K., Watanable, T. Studies of aculeacin. II. Isolation and characterization of aculeacins B, C, D, E, F and G. J Antibiot 1977; 30: 303-307.
86. Mukhopadhyay, T., Ganguli, B.N. Mulundocandin, a new lipopeptide antibiotic. II. Structure elucidation. J Antibiot 1986; 40: 281-289.
87. Roy, K., Mukhopadhyay, T., Reddy, G.C.S., Desikan, K.R., Ganguli, B.N. Mulundocandin, a new lipopeptide antibiotic. I. Taxonomy, fermentation, isolation, and characterization. J Antibiot 1986; 40: 275-280.
88. Mukhopadhyay, T., Roy, K., Bhat, R.G. y cols. Deoxymulundocandin - A new echinocandin type antifungal antibiotic. J Antibiot 1992; 45: 618-623.
89. Iwamoto, T., Fuji, A., Nitta, K., Hashimoto, S., Okuhara, M., Kohsaka, M. WF11899A, B and C novel antifungal lipopeptides. II. Biochemical properties. J Antibiot 1994; 47: 1092-1095.
90. Stone, J.A., Holland, S.D., Wickersham, P. J. y cols. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-745.
91. Walsh, T.J., Adamson, P.C., Seibel, N.L. y cols. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49: 4536-4545.
92. Seibel, N.L., Schwartz, C., Arrieta, A. y cols. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317-3324.
93. Hebert, M.F., Blough, D.K., Townsend, R.W. y cols. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 1018-1024.
94. Mora-Duarte, J., Betts, R., Rotstein, C. y cols. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
95. Ratanatharathom, V., Flynn, P., Van Burik, J. A., McSweeney, P., Niederwieser, D., Kontoyiannis, D. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. 44th Annual American Society of Hematology Meeting, Philadelphia, PA, USA 2002; Abstr. 722.
96. Villanueva, A., Arathoon, E.G., Gottuzzo, E., Berman, R.S., DiNubile, M.J., Sable, C.A. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidat esophagitis. Clin Infect Dis 2001; 33: 1529-1535.
97. Chryssanthou, E., Cuenca-Estrella, M. Comparison of the antifungal susceptibility testing subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazol and caspofungin susceptibility testing of yeast species. J Clin Microbiol 2002; 40: 3841-3844.
98. Villanueva, A., Gotuzzo, E., Arathoon, E.G. y cols. A randomized double blind study of caspofungin versus fluconazole for the treatment ofesophageal candidiasis. Am J Med 2002; 113: 294-299.
99. Arathoon, E.G., Gotuzzo, E., Noriega, L.M., Berman, R.S., DiNubile, MJ., Sable, C.A. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharingeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46: 451-457.
100. Letscher-Bru, V, Herbrecht, R. Caspofungin: The first representative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513-521.
101. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast; approved standard, 2nd ed. NCCLS document M27-A2, NCCLS, Wayne, PA 2002.
102. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A, NCCLS, Wayne, PA 2002.
103. Lumbreras, C., Lizosain, M., Aguado, J.M. Antifúngicos de uso sistémico. Enferm Infecc Microbiol Clin 2003; 21: 366-380.
104. Balani, S.K., Xu, X., Arisen, B.H. y cols. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000; 28: 1274-1278.
105. Hajdu, R., Thompson, R., Sundelof, J.G. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (743,872). Antimicrob Agents Chemother 1997; 41: 2339-2344.
106. Bowman, J.V., Abruzzo, G.K., Anderson, J.W. y cols. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474-3481.
107. Goldblum, D., Frueh, B.E., Sarra, G.M. y cols. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob Agents Chemother 2005; 49: 1359-1363.
108. Schwartz, M., Kline, W., Matuszewski, B. Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high performance liquid chromatography with fluorescence detection. Anal Chim Acta 1997; 352: 299-307.
109. Stone, J.A., Holland, S.D., Wickersham, P.J. y cols. Single- and multiple-dose pharmacokinetics in healthy men. Antimicrob Agents Chemother 2002; 46: 739-745.
110. Abruzzo, G.K., Flattery, A.M., Gill, C.J. y cols. Evaluation of the echinocandin antifungal MK-0991 (L-743872): Efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob Agents Chemother 1997; 41: 2333-2338.
111. Powles, M.A., Liberator, P., Anderson, J. y cols. Efficacy of MK-0991 (L-743,872), a semisynthetic pneumocandin, in marine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42: 1985-1989.
112. Graybill, J.R., Najvar, L.K., Montalbo, E.M Treatment of histoplasmosis with MK-0991 (L-743,872). Antimicrob Agents Chemother 1998; 42: 151-153.
113. Kohler, S., Wheat, L.J., Connolly, P. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a marine model. Antimicrob Agents Chemother 2000; 44: 1850-1854.
114. González, G.M., Tijerina, R., Najvar, L.K. y cols. Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001; 45: 1854-1859.
115. Mattiuzzi, G.N., Riehl, T.D., Pierce, S.R. y cols. Itraconazole versus caspofungin for prophylaxis of invasive fungal infections in patients with acute myelogenous leukaemia and myelodysplastic syndromes undergoing induction chemotherapy. Blood 2003; 100: 332a.
116. Trenshel, R., Ditschkowski, M., Elmaagacli, A. y cols. Caspofungin after allogeneic stem cell transplantation: A single centre experience of 21 patients treated for fever of unknown origin or invasive mycosis. Blood 2003; 100: 439b.
117. Mattiuzzi, G.N., Kantarjian, H., O'Brien, S. y cols. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004; 100: 568-573.
118. Trenschel, R., Ditschkowski, M., Elmaagacli, A.H. y cols. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 35: 583-586.
119. Sable, C.A., Nguyen, B.Y.T., Chodakewitz, J., Dinubile, M. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.